510(k) device
MoFi Cell Culture Basal Medium
Duogenic Stemcells Corporation · Media, Culture, Ex Vivo, Tissue And Cell (NDS, Class II) · First FDA decision Jul 12, 2024, newest Jul 12, 2024Infertility
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
510(k) pathway
Device trials
0
Naming "MoFi"
MAUDE reports
0
Brand "MoFi", since 2015
PubMed studies
10
Mentioning "MoFi"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing MoFi Cell Culture Basal Medium
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
K240247 · Decided Jul 12, 2024 · 164 days after receipt
Device type: Media, Culture, Ex Vivo, Tissue And Cell (NDS) · GI, Urology & Nephrology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Ultrafiltration, Hemoperfusion and HemofiltrationNational determinationOn the books110.15Updated Aug 17, 2023
Clinical trials
Device studies on ClinicalTrials.gov that name "MoFi", any status and sponsor, newest update first.
No registered device study names "MoFi".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "MoFi", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code NDS
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "MoFi"[tiab]. The summary above synthesizes these.
- Enriched Peripheral Blood-Derived Mononuclear Cells for Treating Knee Osteoarthritis.
Chuang CH, Kuo CC, Chiang YF, et al. · Cell Transplant · 2023Research Support, Non-U.S. Gov't
- "Small is beautiful" - Examining reliable determination of low-abundant therapeutic antibody glycovariants.
Böttinger K, Regl C, Schäpertöns V, et al. · J Pharm Anal · 2024
- Automatic Skull-Template Alignment Without a Guidance Image.
Bates O, Cueto C, Coleman C, et al. · Ultrasound Med Biol · 2026
- MOFI-FL, a novel score for detecting hepatic steatosis and predicting cardiometabolic mortality.
Reyes-Barrera J, Posadas-Sánchez R, Vargas-Alarcón G, et al. · Sci Rep · 2025
- Use of Therapeutic Plasma Exchange during Extracorporeal Life Support in Critically Ill Cardiac Children with Thrombocytopenia-Associated Multi-Organ Failure.
Chong M, Lopez-Magallon AJ, Saenz L, et al. · Front Pediatr · 2017
- Glycoproteomics of a Single Protein: Revealing Tens of Thousands of Myozyme Glycoforms by Hybrid HPLC-MS Approaches.
Di Marco F, Blöchl C, Esser-Skala W, et al. · Mol Cell Proteomics · 2023Research Support, Non-U.S. Gov't
- MoFi: A Software Tool for Annotating Glycoprotein Mass Spectra by Integrating Hybrid Data from the Intact Protein and Glycopeptide Level.
Skala W, Wohlschlager T, Senn S, et al. · Anal Chem · 2018Research Support, Non-U.S. Gov't
- 3D-Printed Metal-Organic Framework/Polymer Catalytic Filters for Detoxification of Nerve Agent Simulants.
Tsipoaka M, Aina PO, Rownaghi AA, et al. · ACS Appl Mater Interfaces · 2025
- Amine-Functionalized Al-MOF#@ yxSm2O3-ZnO: A Visible Light-Driven Nanocomposite with Excellent Photocatalytic Activity for the Photo-Degradation of Amoxicillin.
Abazari R, Mahjoub AR · Inorg Chem · 2018
- Association between metal co-exposure and frailty: exploring the potential explanatory pathway of inflammation.
Yu D, Wei Y, Zhou YF, et al. · Biometals · 2026
Other devices of this type
Also filed under product code NDS.
- Msc SfmYocon Biology Technology Company · 510(k) 2024
- PRIME-XV FreezIS DMSO-Free MDFujifilm Irvine Scientific · 510(k) 2023
- Ct-StorEnergy Delivery Solutions · 510(k) 2021
- Optmizer Cts T-Cell Expansion Serum Free MediumLife Technologies, Inc. · 510(k) 2012
- Stempro Msc SfmLife Technologies Corporation · 510(k) 2011
- Knockout Sr Medium, Knockout Sr Xenofree Medium Model 10828, 12618Life Technologies Corporation · 510(k) 2010
- Aim-V (R) Medium, Model 087-0112Invitrogen Corporation · 510(k) 2002
- Dulbecco's Modified Eagle Medium (Dmem)Life Technologies, Inc. · De Novo 2001
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.